Hepatocellular carcinoma developed in dysmetabolic hepatopathy: Epidemiology and physiopathological mechanisms
Pages 353 to 360
Cite this article
- DESJONQUÈRES, Elvire,
- NAULT, Jean-Charles,
- NAHON, Pierre,
- GANNE, Nathalie
- and GIGANTE, Elia,
- Desjonquères, Elvire.,
- et al.
- Desjonquères, E.,
- Nault, J.-C.,
- Nahon, P.,
- Ganne, N.
- and Gigante, E.
https://doi.org/10.1684/hpg.2022.2342
Cite this article
- Desjonquères, E.,
- Nault, J.-C.,
- Nahon, P.,
- Ganne, N.
- and Gigante, E.
- Desjonquères, Elvire.,
- et al.
- DESJONQUÈRES, Elvire,
- NAULT, Jean-Charles,
- NAHON, Pierre,
- GANNE, Nathalie
- and GIGANTE, Elia,
https://doi.org/10.1684/hpg.2022.2342
The global epidemiology of hepatocellular carcinoma in recent decades has been marked by the emergence of non-alcoholic fatty liver disease (NAFLD), alongside an increase in obesity and type 2 diabetes. Today, NAFLD is the main cause of chronic hepatopathy worldwide, ahead of viral hepatitis and alcohol consumption, as well as one of the principal etiologies of hepatocellular carcinoma (HCC), especially in Western countries. In this review, we present the latest data on the epidemiology of dysmetabolic hepatopathy and hepatocellular carcinoma resulting from NAFLD, and discuss the main clinical and molecular features leading to the progression of liver disease and the development of HCC in NAFLD. In a dedicated paragraph, we discuss the therapeutic specificities of HCC developed on NASH. The emerging concept of metabolic-associated fatty liver disease (MAFLD) and its link with the development of HCC are also introduced.